Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 31% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $83,896 and 14, calls, for a total amount of $868,516.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $350.0 to $500.0 for Vertex Pharmaceuticals over the recent three months.
Volume & Open Interest Trends
In today's trading context, the average open interest for options of Vertex Pharmaceuticals stands at 137.17, with a total volume reaching 479.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Vertex Pharmaceuticals, situated within the strike price corridor from $350.0 to $500.0, throughout the last 30 days.
Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| VRTX | CALL | TRADE | BULLISH | 01/16/26 | $71.0 | $62.0 | $68.53 | $500.00 | $171.3K | 226 | 50 |
| VRTX | CALL | TRADE | BULLISH | 06/07/24 | $15.4 | $10.3 | $14.8 | $455.00 | $148.0K | 35 | 108 |
| VRTX | CALL | TRADE | BULLISH | 01/16/26 | $95.0 | $91.0 | $95.0 | $440.00 | $95.0K | 33 | 10 |
| VRTX | CALL | TRADE | BEARISH | 06/21/24 | $38.2 | $36.4 | $36.4 | $430.00 | $72.8K | 310 | 35 |
| VRTX | CALL | TRADE | BEARISH | 01/17/25 | $58.1 | $56.0 | $56.0 | $450.00 | $56.0K | 507 | 11 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
After a thorough review of the options trading surrounding Vertex Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Vertex Pharmaceuticals
- Currently trading with a volume of 1,171,708, the VRTX's price is up by 2.76%, now at $467.93.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 57 days.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
擁有大量資金的大戶已經明顯看好福泰製藥。
查看納斯達克的福泰製藥（NASDAQ: VRTX）選項歷史，我們檢測到16筆交易。
如果我們考慮每次交易的具體情況，可以準確地說明50%的投資者帶着看漲的期望開了交易，31%的人看跌。
從全部進行的交易中，有2個看跌，總金額爲$83,896，14個看漲，總金額爲$868,516。
價格目標是什麼？
根據交易活動，顯然有意向投資福泰製藥的重要投資者在最近三個月內瞄準從$350.0到$500.0的價格區間。
成交量和持倉量趨勢。
在今天的交易中，福泰製藥期權的平均持倉爲137.17，總成交量達到479.00。附圖描述了福泰製藥的看漲和看跌期權成交量和持倉量的進展情況，位於從$350.0到$500.0的行權價格區間內，過去30天內的高價值交易。
福泰製藥期權成交量和持倉量過去30天
最大的期權交易：
標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|
納斯達克 | 看漲 | 交易 | 看好 | 01/16/26 | $71.0 | $62.0 | $68.53 | $500.00 | $171.3K | 226 | 50 |
納斯達克 | 看漲 | 交易 | 看好 | 06/07/24 | $15.4 | $10.3 | $14.8 | $455.00 | $148.0K | 35 | 108 |
納斯達克 | 看漲 | 交易 | 看好 | 01/16/26 | $95.0 | $91.0 | 95.0美元 | $440.00 | 95.0千美元 | 33 | 10 |
福泰製藥 | 看漲 | 交易 | 看淡 | 06/21/24 | 38.2美元 | 36.4美元 | 36.4美元 | $430.00 | $72.8K | 310 | 35 |
福泰製藥 | 看漲 | 交易 | 看淡 | 01/17/25 | 58.1美元 | 56.0美元 | 56.0美元 | $450.00 | $56.0K | 507 | 11 |
關於Vertex Pharmaceuticals
福泰製藥是一家全球性的生物技術公司，致力於發現和開發用於治療嚴重疾病的小分子藥物。其關鍵藥品有Kalydeco、Orkambi、Symdeko和Trikafta/Kaftrio用於囊性纖維化病的治療，在全球範圍內均爲福泰製藥的標準板。福泰製藥通過基因編輯療法Casgevy使其投資組合多樣化，用於治療β地中海貧血和鐮狀細胞症。此外，福泰製藥正在評估通過非阿片類治療使用小分子抑制劑治療急性和慢性疼痛和APOL1介導的腎臟疾病，同時，福泰製藥也在研究細胞治療以提供1型糖尿病的潛在功能型治癒方案。
在對福泰製藥的期權交易進行全面審查後，我們進一步研究該公司的內部基本情況和業績。
福泰製藥的現狀
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
